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SUMMARY
Pleomorphic adenoma (PA) is the most common tumour of the salivary glands, and can recur even after proper surgery. The extent and 
timing of surgery for recurrent tumours remains controversial, and multiple recurrences pose a special challenge. We evaluated all recurrent 
PAs (RPAs) treated at the Helsinki University Hospital through 2004-2013 focusing on patients with multiple recurrences. Follow-up data 
were obtained until January 2018. Of the 47 patients, 70% were women and the median age was 33.5 years. Most of the RPAs were located 
in the parotid gland (87%), and six (13%) in the submandibular gland. One-third (17/47) of tumours had been primarily excised. This 
patient population experienced 75 recurrent events in total with two or more recurrences in 14 patients (30%). The time interval between 
recurrences shortened after each recurrent event and the tumour was more likely to be multifocal. At the end of the follow-up period, 15% 
had recurrent disease and malignant transformation had occurred in 6%. Treatment for PA and RPA is challenging and requires centralised 
management. Patients with RPA are often young and recurrences may cause lifelong morbidity, especially when the tumour recurs repeat-
edly. The utilisation and timing of postoperative radiotherapy needs to be discussed as well as the potential risk for malignant transforma-
tion in this patient population. 
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RIASSUNTO 
L’adenoma pleomorfo è il tumore più frequente delle ghiandole salivari. È caratterizzato da un elevato rischio di recidiva anche dopo 
un’accurata chirurgia. L’estensione ed il corretto timing della chirurgia è controverso sopratutto nei casi di tumori plurirecidivanti. In 
questo lavoro abbiamo valutato tutti i casi di adenoma pleomorfo plurirecidivante (RPAs) trattati presso l’Helsinki University Hospital 
dal 2004 al 2013. I dati di follow-up sono stati raccolti sino al gennaio 2018. Dei 47 pazienti considerati, 70% erano donne con un’età 
media di 33,5 anni. La maggior parte dei RPAs erano localizzati a livello della ghiandola parotide (87%), sei (13%) a livello delle ghian-
dole sottomandibolari. Un terzo (17/47) dei tumori sono stati rimossi chirurgicamente. All’interno di questa popolazione di pazienti sono 
stati documentati 75 eventi di recidiva di malattia, 14 pazienti (30%) hanno avuto 2 o più recidive. L’intervallo di tempo intercorso fra le 
singole recidive si è gradualmente accorciato con un incremento progressivo del rischio che il tumore si ripresentasse a livello multifocale. 
Al termine del periodo di follow up, 15% dei pazienti hanno avuto recidiva di malattia, nel 6% si è verificata la degenerazione maligna del 
tumore. Il trattamento dell’adenoma pleomorfo plurirecidivante rappresenta una sfida terapeutica e richiede un management centralizzato. 
I pazienti affetti da RPA sono spesso di giovane età, il trattamento delle forme plurirecidivanti è gravato da un’elevata morbidità negli anni. 
L’impiego ed il timing di un’eventuale radioterapia post operatoria nonchè il rischio di degenerazione maligna sono parametri da prendere 
in considerazione per una corretta gestione multidisciplinare dei RPA. 
PAROLE CHIAVE: Ghiandole salivari • Adenoma pleomorfo • Adenoma • Trattamento • Risultati
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Introduction
Pleomorphic adenoma (PA) is the most common tumour 
of the salivary glands with an incidence rate between 4.2-
4.9/100,000 person-years  1  2. Recurrences occur despite 
proper surgery. Treatment of recurrent PA (RPA) remains a 
challenge, and some tumours may even be incurable. The 
occurrence of satellite nodules and pseudopodia of PA may 
occur due to incomplete capsule of the tumour 3, which may 
lead to residual disease, especially after limited surgery such 
as enucleation. Rupture of the capsule results in spillage of 
tumour cells and increases the risk for recurrences 14- to 
21-fold 4 5. Also, positive surgical margins increase the risk 
of recurrence, but in these circumstances the term residual 
disease instead of recurrence may be more accurate. In close 
proximity of a tumour of the parotid gland to the facial nerve 
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(FN), the tumour needs to be dissected extracapsularly  6, 
which may result in recurrences even after proper superficial 
parotidectomy (SP). Since not all tumours with rupture of the 
tumour capsule recur, and some recur after adequate surgery, 
the causes for RPA seem multifactorial.
Some studies report that age 7 8 and gender 8 have an influ-
ence on the potential of PA to recur, but others show no in-
fluence  4 5 9. Controversies exist between the risk for RPA 
and cellular composition of PA primarily. The most likely 
reasons for RPA to date are rupture of the capsule leading to 
tumour spillage and positive surgical margins 4, although as 
pointed by Colella et al. 10, studies supporting this conception 
are limited. The abandonment of enucleation and preferring 
more extended surgery seem to have led to a dramatically 
decreased recurrence rate of PA from up to 45% to as low 
as 1% 5 6 10. Favouring extracapsular dissection (ECD) nowa-
days in parotid PA over routine SP does not result in a higher 
recurrence rate 6 10, but does minimise the risk for FN dys-
function and other complications  11. Furthermore, a recent 
meta-analysis on parotid PAs reported that the recurrence 
rate after ECD was half that after SP in experienced hands 10.
The aim of the present study was to evaluate RPA treat-
ed at our institution over a 10-year period. We report the 
treatment and outcome of 47 consecutive patients and 
discuss the reasons for recurrences and treatment of RPA 
with special focus on multiple recurrences. 
Patients and methods
Patients with any recurrence of PA diagnosed at the Hel-
sinki University Hospital between January 1, 2004 and 
January 1, 2014 were included. We collected information 
on patient demographics, clinical history, diagnostics, 
clinical and pathological features of tumours, recurrenc-
es and their treatment, FN function and follow-up data. 
To gather further follow-up data after diagnosis of RPA, 
all events until January 2018 were recorded. This study 
was approved by the institutional Research Ethics Board 
(192/13/03/02/16) and study permission was granted.
During the study inclusion period, 47 patients with RPA 
were diagnosed. During the same period, 796 patients 
were operated for a benign salivary gland PA, including 
the RPAs, at our institution. 
We included also RPA with malignant changes, i.e. CX-
PA. An additional search revealed 14 patients with CXPA 
during the period, but only one had presented with a pre-
viously treated PA. 
Results
Of the 47 patients, 33 were women (70%) and 14 were 
men (30%). The median age at time of diagnosis of the 
primary tumour was 33.5 years (range, 10-65). Most of 
the tumours were located in the parotid gland (n  =  41; 
87%), and six (13%) in the submandibular gland. We 
found no RPAs of the minor salivary glands. Altogether, 
75 recurrent events occurred in this patient population. Of 
all patients, 33 had one recurrence, seven had two, four 
had three, one had four, one had five and one patient ex-
perienced seven recurrences. In 41 patients, the primary 
surgery had been carried out before the study inclusion 
period (January 1, 2004) (Fig. 1). Of the recurrent events, 
12 occurred before this date, and further recurrences after 
the study inclusion period were diagnosed in two patients. 
Primary tumours and treatment
The initial treatment of the primary tumours was per-
formed during 1969-2009 by various head and neck sur-
geons. In 23 cases, treatment had been executed at other 
institutions, even some in other countries (n = 4), limiting 
available information on the initial phase of treatment. 
Of the 41 parotid gland tumours, 38 were initially located 
in the superficial lobe, two in the deep lobe and one was 
extended to both lobes. Surgery of parotid gland tumours 
consisted of removal of the tumour only in 15 patients, 
superficial or partial parotidectomy in 22 patients and to-
tal parotidectomy in three patients. In one patient, surgi-
cal data remained unavailable. Of the six patients with a 
submandibular gland tumour, four had had removal of the 
gland with the tumour, and two had had limited surgery 
with a purpose of tumour removal only. 
Rupture of the tumour capsule and direct spillage of tu-
mour cells was reported in eight (17%) patients. None of 
the primary tumours were multifocal. 
First recurrence
The median time between primary treatment of the tumour 
and first recurrence was 10.3 years (mean, 13.3; range, 
1.3-39.4). All except one of the 47 patients underwent sur-
gery for the first recurrence. Surgery for 40 parotid gland 
RPAs consisted of resection of single adenomas in 18 pa-
tients (45%), partial or superficial parotidectomy in 15 pa-
tients (38%), total parotidectomy in six (15%) and radical 
surgery in one patient (3%). Surgery for submandibular 
gland RPA included resections of a single adenoma in two 
patients, or at least level I B dissection in four. 
Rupture of the tumour capsule and direct spillage of tu-
mour cells was reported in four cases (9%). In three cases 
surgery was non-radical, and these patients had persistent 
disease at the end of follow-up. On histopathological ex-
amination, positive surgical margins were reported in 19 
cases (41%), and multifocal disease in 27 cases (59%).
K. Aro et al.
158
Radiotherapy (RT) with 60 Gy was administered in three 
patients after a benign recurrent tumour, in all after the 
first recurrence. 
Second and later recurrences
The majority (n = 31; 70%) of the patients had a single 
recurrent event, whereas a second recurrence (i.e two or 
more recurrent events) occurred in 14 (30%) patients. 
11 (79%) emerged in the parotid gland, and three (21%) 
in the submandibular gland. 
Of the 14 patients undergoing additional surgery for sec-
ond recurrence, rupture of the tumour capsule and direct 
spillage of tumour cells was reported in four cases (29%). 
Histopathological examination revealed positive surgical 
margins in two patients (14%), and multifocal disease in 
eight cases (57%). 
A third recurrence (i.e. three or more recurrent events) was 
observed in seven patients (15%), six in the parotid gland 
and one in the submandibular gland. The recurrence was 
multifocal in five of these patients (71%). Further recur-
rences occurred in three patients. Their surgery included 
excision of single adenomas. 
The time interval between recurrences shortened after 
each recurrent event with a median of 5.8 years (mean, 
7.5; range, 1.2-20.1) between the first and the second re-
currence. 
At the end of the follow-up period (January 1, 2018), seven 
patients presented with recurrent disease: one patient who 
had been treated with postoperative RT presented with 
an unchanged parapharyngeal space recurrence within a 
3-year follow up. Surgery had been non-radical in three 
patients with multifocal disease and they had been fol-
lowed up without further treatment. In the remaining three 
cases, multiple tumours after repeated recurrences had 
been followed up and their status had remained almost 
unchanged for 4-9 years.
Carcinoma ex pleomorphic adenoma
Three patients experienced a carcinoma in their recurrent 
tumours. In one patient, this occurred in the first recur-
rence 14 years after the treatment of the primary tumour. 
The patient had two palpable tumours, which had grown 
within 3-4 years, but MRI and histology revealed numer-
ous carcinomatous lesions. In the two other patients, mul-
tifocal carcinoma was diagnosed in the third recurrent 
event. These appeared at 20 and 37 years after the treat-
ment of the primary tumour (7 and 16 years after previ-
ous recurrences). Fine needle aspiration cytology (FNAC) 
was taken in two of these patients, and in one patient it 
was highly suspicious of malignancy and in the other it 
was slightly suspicious.
Discussion
We had 47 RPA cases, 14 of whom (30%) later experi-
enced further recurrences. During our study period, the 
rate of recurrences of all PAs operated on at our institution 
was 6%. However, this does not reflect the true recurrence 
rate, as many of the tumours had initially been operated on 
decades ago, and at several other hospitals. Notwithstand-
ing, our results are in line with Valstar et al. 1 and Colella 
et al. 10. The latter meta-analysis reported the recurrence 
rate to vary according to the type of surgery from 1-8%. 
Women were more often affected in the present study, and 
Fig. 1. Time frames of the diagnosis of the primary tumours and recurrences.
Recurrent pleomorphic adenoma
159
this has also been shown by others  1 2 12 13. Andreasen et 
al. 2 reported in a national study a median age for PA to 
be over 50 years, and showed a tendency for younger age 
among patients who experienced recurrences. This ten-
dency was also obvious in the current study.
We and others nowadays favour MRI as the preferred im-
aging method in RPA 14. It is superior in detecting multi-
nodularity, but the smallest nodules still remain undetect-
able 14. In our series, MRI was used rarely in superficial 
lesions. Instead, ultrasound (US) and US-guided FNAC 
was used in many cases. The sensitivity of FNAC for 
detecting salivary gland neoplasms is generally around 
83% 15, and even higher for PA 16 17, and was 67% in the 
present study (data not shown). Heaton et al. 16 have shown 
that FNAC combined with MRI can offer highly confident 
preoperative diagnosis of PA 16. Of note, Zbären et al. 18 
reported that the sensitivity of FNAC to detect CXPA was 
only 47%, and the malignancy of PA was known preop-
eratively in only 42% of cases. Therefore, FNAC does not 
seem to be adequate in defining the eventual malignant 
nature of a recurrent tumour. In our series, FNAC indi-
cated malignancy correctly, but was obtained in only two 
of three CXPAs.
Basically, despite the surgical method, all techniques for 
superficial parotid PA expose the tumour capsule focally 6. 
A meta-analysis shows that a rupture of the capsule of the 
primary tumour and tumour spillage are strongly associ-
ated with recurrence 6. However, rupture of a capsule does 
not always lead to recurrence, and several reports have 
shown no association of tumour cell seeding with recur-
rences 6 13 19. Dell’Aversana et al. 20 showed that favouring 
ECD in superficial parotid gland tumours instead of SP 
seems to decrease possible postoperative complications, 
but may carry a higher risk for rupture of the capsule 
and an increase in recurrences, although not all support 
this conception 6. In our cohort, surgery for the primary 
tumour included removal of the tumour only in 36% of 
cases. Knowledge of tumour biology and education of the 
appropriate treatment are vital.
In our cohort, tumour spillage after rupture of the capsule 
of the primary tumour was known only infrequently. Ob-
viously, a structured surgical and histopathological work-
sheet should be outlined to complete clinically relevant 
tumour characteristics and possible complications during 
surgery. The primary treatment of PA should therefore 
be carefully planned, executed and centralised in experi-
enced centres. Valstar et al. 1 showed that positive resec-
tion margins increased the risk for recurrence over four-
fold, and Espinosa et al. 13 reported the risk to be even 49 
times higher.
Incomplete capsule, capsule penetration, pseudopodia, or 
satellite tumours are common in PA. Zbären and Stauffer 12 
reported these features to be present in 73% of a cohort of 
218 tumours. Satellite nodules increase the risk for RPA, 
as they are observed in 60% of RPAs compared to 10% in 
non-recurrent tumours 4. Thus, negative surgical margins 
do not guarantee successful surgery in terms of tumour 
recurrence 21. Satellite nodules seem to be more common 
in tumours over 4 cm 4 22 23, as they are observed in 33% 
of such tumours compared to 6-10% in those smaller than 
4 cm 22. We had only two (12%) tumours that were over 
4 cm. Delays in treatment may also increase the size of 
the recurrent tumour and thus increase treatment-related 
complications 24. Some studies show that the myxoid his-
tologic subtype of PA with incomplete encapsulation has a 
higher risk for RPA 12 23 and some show no significance of 
the cellular subtype 4 13, while another study indicated that 
the risk appears to be higher in hypercellular tumours 7.
Multinodular tumours and tumours with local excision 
only are more likely to recur repeatedly  9. Redaelli de 
Zinis et al.  9 reported an overall recurrence rate of 33% 
for second recurrences, reflecting our results (32%). None 
of their patients with a parotid RPA with a single node 
recurred. They found that patients with multiple nodules 
who did not undergo at least SP were at higher risk to re-
cur. In our cohort, after every recurrence, the tumour was 
more often multifocal and thus complicating the surgical 
treatment. Thus, limited surgery consisting of resection 
of single nodules was more often executed in the second 
recurrence. 
Additional surgery for RPA increases the risk for FN pa-
ralysis  8 14. This was also obvious in our patient cohort, 
but comprehensive data were difficult to extract retrospec-
tively from hospital records. A recent prospective study 
assessing the complications of parotid gland surgery re-
ported immediate postoperative FN paralysis in 40% of 
patients when the slightest changes were taken into ac-
count  25, although nerve monitoring and the use of mi-
croscope decrease the risk  26. A review by Witt et al.  14 
revealed that after surgery of a parotid gland RPA, tempo-
rary FN injury occurred in 90-100%, and permanent FN 
injury in 11-40% of cases. This highlights the importance 
of adequate treatment of RPA in the first recurrent event.
Postoperative RT should be discussed in cases of PA 
with negative prognostic factors  27. In some cases RT 
is an option to preserve FN function  28, and some have 
administered RT for PA with close or positive surgical 
margins  29 30 with good local control. Witt et al.  14 sum-
marised local tumour control after postoperative RT and 
it seems that RT improves treatment outcomes in patients 
with multinodular tumours with several recurrences. RT 
should be administered after surgery: Douglas et al.  31 
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reported postoperative RT to result in a 100% 15-year 
locoregional control among patients with microscopic 
disease compared to 76% for patients with macroscopic 
disease. Many studies included only a few patients who 
received RT. Conclusions on indications of RT are thus 
hard to outline. Furthermore, it is unclear after which 
recurrent event is RT beneficial and should be recom-
mended. Also, since patients usually present tumours at 
an early age, the side effects of RT need to be considered, 
and whether RT can induce the growth of other nodules 
in the future. We had only three patients who received RT 
for benign RPA. Furthermore, half of the patients who 
had a second recurrence developed further recurrences, 
and even malignancy. Thus, we might speculate that more 
extensive utilisation of postoperative RT could have de-
ferred further recurrences. Based on the results from our 
series and the current literature, postoperative RT seems 
warranted in multifocal recurrent disease and in patients 
for whom additional surgery would most likely cause 
significant morbidity. We had several patients who had 
been followed up after detection of repeated recurrence. 
Among these, additional surgery was considered impos-
sible without sacrifice of the facial nerve, and RT was not 
optimal because of macroscopic disease. It is noteworthy 
that even 6% of patients in our series developed CXPA 
and patients in follow-up are still in high risk of develop-
ing a malignancy. This clinical dilemma supports admin-
istration of postoperative RT for RPA.
The majority of CXPA are diagnosed as de novo cases 2 18, 
although PA may undergo malignant transformation with 
an increased risk over time 14. If PA is left untreated, re-
cent studies show that the risk for malignant transforma-
tion is generally considered to be around 1.1-1.7%  1  2. 
RPA gains potential for malignant transformation after re-
peated recurrences 14 21. On the other hand, 12% of CXPA 
have been shown in patients with a previous operation for 
PA, and the rate of malignant transformation in RPA has 
been reported around 3-4% 32, reflecting the results of the 
present study. As Suh et al. 21 show, younger patients are at 
higher risk for developing recurrences and therefore ma-
lignancies in the future. 
The causes which lead to subsequent recurrences occur 
most likely at the time of the primary surgery 27, but the 
subsequent recurrences become clinically evident later. 
Therefore, we can contemplate that treatment of RPA had 
been inadequate in several cases. The mean time inter-
val from the treatment of the primary tumour to diagnosis 
of first recurrence was as long as 12 years in the present 
study. Another study also reported that tumours common-
ly recur more than 10 years after initial surgery 19. Zbären 
et al. 7 reported a mean nine-year interval between the first 
and second recurrence, reflecting the mean 7.5-year inter-
val in the present study, but a recent study reported a much 
shorter interval of two years 1. The time interval between 
recurrences in our cohort, however, shortened after every 
recurrence, as reported in another study 21. We can specu-
late whether a follow-up period instead of immediate 
surgery after detection of RPA would be warranted. This 
could reveal whether there will appear several additional 
lesions since MRI fails to show all small nodules. Thus, 
the extent of surgery could be planned more adequately to 
avoid multiple surgeries. Significant morbidity after ad-
ditional surgery probably limits the desire to proceed with 
more radical surgery among young patients. 
Conclusions
Treatment for PA, and especially RPA, is challenging, 
and surgery of salivary gland tumours thus needs to be 
centralised. Patients with RPA are often young and recur-
rences may cause lifelong morbidity, especially in cases 
with multiple recurrences. Thus, in some cases, follow-up 
instead of additional surgery might be an option. The role 
of RT in the management of RPA needs consideration as 
the risk for malignant transformation is significant. Future 
research is required to develop new follow-up methods 
and management options for RPA in order to avoid further 
recurrences. 
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